Azenta, Inc. (AZTA)
NASDAQ: AZTA · Real-Time Price · USD
46.42
-0.79 (-1.67%)
Dec 3, 2024, 1:44 PM EST - Market open
Azenta Revenue
In the fiscal year ending September 30, 2024, Azenta had annual revenue of $656.32M, down -1.32%. Azenta had revenue of $170.06M in the quarter ending September 30, 2024, a decrease of -1.33%.
Revenue (ttm)
$656.32M
Revenue Growth
-1.32%
P/S Ratio
3.82
Revenue / Employee
$187,521
Employees
3,500
Market Cap
2.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 656.32M | -8.75M | -1.32% |
| Sep 30, 2023 | 665.07M | 109.57M | 19.73% |
| Sep 30, 2022 | 555.50M | 41.80M | 8.14% |
| Sep 30, 2021 | 513.70M | 125.17M | 32.21% |
| Sep 30, 2020 | 388.54M | 54.36M | 16.27% |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teladoc Health | 2.59B |
| Astrana Health | 1.72B |
| Omnicell | 1.06B |
| Tandem Diabetes Care | 854.35M |
| Amphastar Pharmaceuticals | 723.55M |
| Supernus Pharmaceuticals | 651.97M |
| NovoCure | 577.74M |
| GeneDx Holdings | 267.23M |
AZTA News
- 13 days ago - Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600 - PRNewsWire
- 19 days ago - Azenta to Participate in Stephens Annual Investment Conference - PRNewsWire
- 20 days ago - Azenta, Inc. (AZTA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Azenta Reports Fourth Quarter and Full Year Fiscal 2024 Results; Announces the Plan to Sell B Medical Systems and Appoints Lawrence Y. Lin as CFO - PRNewsWire
- 4 weeks ago - Azenta Announces Fiscal 2024 Fourth Quarter and Full Year Earnings Conference Call and Webcast - PRNewsWire
- 4 weeks ago - Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value - PRNewsWire
- 4 weeks ago - Azenta Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test - PRNewsWire
- 3 months ago - AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO - PRNewsWire